

From: HMA Permanent Secretariat [<mailto:hma-ps@imb.ie>]

Sent: Monday, March 24, 2014 3:15 PM

To: SANCO PHARMACEUTICALS D5

Subject: FW: Study on the availability of medicinal products for human use across the EU

Importance: High

Dear colleagues,

as regards the contracted report, we welcome it in general, but further discussion on the outcomes should follow (e.g. Art. 81 and 126a and their applicability).

To the second question on Art. 126a - the Czech Republic has not yet used this provision to authorise medicinal products.

With kind regards

Doubravka Kostalova

Dr. Doubravka Kostalova

European Regulatory Affairs Manager

EMA MB, HMA PS

STATE INSTITUT

FOR DRUG CONTROL

[Doubravka.kostalova@sukl.cz](mailto:Doubravka.kostalova@sukl.cz)

[www.sukl.cz](http://www.sukl.cz)